Patent ID: 11952411
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The engineered TL1A ligand of claim 1 comprising: a first means capable of binding DR3 with an affinity comparable to or higher than the affinity of wildtype TL1A and a second means capable of binding DcR3 with an affinity lower than the affinity of wildtype TL1A, wherein optionally:
(i) the engineered TL1A ligand has a longer serum half-life than wildtype TL1A;
(ii) the engineered TL1A ligand has a high monodispersity and/or stability compared to wildtype TL1A;
(iii) the engineered TL1A ligand co-stimulates T cells in vitro;
(iv) the engineered TL1A ligand co-stimulates T cells in a subject; and/or
(v) the engineered TL1A ligand increases production of one or more cytokines in a subject, wherein optionally the one or more cytokines comprise IFNy and TNFa, wherein optionally the subject has an autoimmune disorder or cancer optionally selected from the group consisting of ulcerative colitis, lupus, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), arthritis, multiple sclerosis, diabetes, transplant rejection, central nervous system injury, Crohn's disease, psoriasis, leukemia or lymphoma, atherosclerosis, colon cancer, breast cancer, pancreatic cancer, leukemia, lung cancer such as non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, gastric cancer, pituitary adenomas, ovarian cancer, renal cancer, bladder cancer, and a sarcoma, wherein optionally the sarcoma is a rhabdomyosarcoma, and wherein optionally the subject is a subject in need thereof.